Behcet’s Disease: A Multifaceted Affliction
DOI:
https://doi.org/10.61427/jcpr.v1.i3.2021.32Keywords:
Behcet’s disease, Inflammation, Pathergy test, Ulcers, VasculitisAbstract
Behcet’s disease is a rare systemic vasculitic disorder characterized by a triad of symptoms that includes recurrent mouth ulcers, genital ulcers and inflammation of uvea. The prevalence of this disease tends to be high in the third or fourth decades of life. Genetic and environmental factors may influence the development and progression of this disease. In this article, the involvement of the signs and symptoms of oral, genital, dermatological, musculoskeletal, gastrointestinal, ocular, neurologic, vascular and cardiac systems were reviewed along with the diagnosis and treatment of this disease. Diagnosis is quite complex due to the lack of specific laboratory, radiological and histological findings. Hence, the diagnosis can be completely depends upon the existing clinical features of that particular individual. Pathergy test is considered as an optional diagnostic test in the diagnosis of this disease due to the differences in the evaluation and application of the test. The treatment of Behcet’s disease varies with organs involved, severity of lesion and clinical manifestations associated with the patients. There is no cure for this disease and all the available treatments are mainly focused in resolving symptoms and recurrence. Since this condition is rare, the health care professionals should have regular discussions regarding the treatment goals for better therapeutic outcome and to prevent the further complications. Proper coordination and communication among the health care professionals of various departments is a prerequisite for effective therapy as this disease requires a periodic monitoring of multidisciplinary approach.
Downloads
References
Smith EL, & Yazici Y. Pathogensis of Behcet’s Syndrome. UpToDate. January 17, 2017.
Calamia KT. Behcet's Syndrome. National Organization for Rare Disorders (NORD). 2018.
NINDS Behcet's Disease Information Page. National Institute of Neurological Disorders and Stroke (NINDS). 2017.
Bashour M. Ophthalmolgic Manifestations of Behcet;s Disaese Treatment & Management. Medscape Reference. 2016.
Esatoglu SN, Kutlubay Z, Ucar D, Hatemi I, Uygunoglu U, Siva A, et al. Behcet’s syndrome: providing integrated care. Journal of multidisciplinary healthcare. 2017:10.
Hatemi G, Yazici Y, Yazici H. Behcet’s syndrome. Rheum Dis Clin North Am. 2013; 39(2): 245-61.
Saadoun D, Wechsler B, Desseaux. Mortality in Behcet’s disease. Arthritis Rheumatol. 2010; 62(9): 2806-12.
Gulsen Akman-Demir, Piraye Serdaroglu, Banu Tasci. Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. Brain. 1999; 122: 2171-81.
O Duffy JD. Vasculitis in Behcet’s disease. Rheum Dis Clin North Am. 1990; 16: 423-31.
Ehrlich GE. Vasculitis in Behcet’s disease. Int Rev Immunol. 1997; 14: 81-8.
Hadfield MG, Aydin F, Lippman HR, Sanders KM. Neuro-behcets’s disease. Clin Neuropathol. 1997; 16: 55-60.
Rubinstein LJ, Urich H. Meningo-encephalitis of Behcet’s disease: case report with pathological findings. Brain. 1963; 86: 151-60.
Sugihara H, Muto Y, Tsuchiyama H. Neuro-Behcet’s syndrome: report of two autopsy cases. Acta Pathol Jpn. 1969; 19: 95-101.
Powell RJ, Dunstan S. Immunopathology of Behcet’s disease. Postgrad Med J. 1991; 67: 503-5.
Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in behcet’s disease. Br J Dermatol. 1995; 132: 901-7.
Yurdakul S, Yazici H. Behcet’s syndrome. Best Pract Res Clin Rheumatol. 2008; 22(5): 793-809.
Rokutanda R, Kishimoto M, Okada M. Update on the diagnosis and management of Behcet’s disease. Open Access Rheumatology: Research and Review. 2015:7.
Yazici H, Tuzun Y, Pazarli H. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Ann Rheum Dis. 1984; 43(6): 783-9.
Bonitsis NG, Luong Nguyen LB, LaValley MP. Gender-specific differences in Adamantiades-Behcet’s disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology (Oxford). 2015; 54(1): 121-33.
Adil A, Quint JM. Behcet’s Disease. [Updated 2019 Nov 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019.
Nair JR, Moots RJ. Behcet’s disease. Clin Med (Lond). 2017; 17(1): 71-7.
Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behcet’s syndrome in Hawaii with particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J. 1975; 34(7): 244-46.
Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition of Behcet’s disease. Int Rev Immunol. 1997; 14(1): 33-48.
Yazici H, Akokan G, Yalcin B, Muftuoglu A. The high prevalence of HLA-B5 in Behcet’s disease. Clin Exp Immunol. 1977; 30(2): 259-61.
Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet’s disease in Turkey. Ann Rheum Dis. 2000; 59(8): 622-25.
Remmers EF, Cosan F, Kirino Y. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet. 2010; 42(8): 698-702.
Mizuki N, Meguro A, Ota M. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010; 42(8): 703-6.
De Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLAB51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheumatol. 2009; 61(10): 1287-96.
Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012; 51(5): 887-900.
Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet’s disease. Int Rev Immunol. 1997; 14(1): 21-32.
Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet’s disease. Clin Exp Immunol. 1990; 79(1): 28-34.
Nussenblatt RB. Uveitis in Behcet’s disease. Int Rev Immunol. 1997; 14(1): 67-79.
A. Gul. Behcet’s disease:an update on the pathogensis. Clinical and Experimental Rheumatology. 2001; 19(24): S6-S12.
Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behcet’s disease: immunological aspects. Yonsei Med J. 1997; 38: 350-8.
Lehner T. Immunopathogenesis of Behcet’s disease. Ann Med Interne (Paris). 1999; 150: 483-7.
Mohamad J, Zeidan, David Saadoun, Marlene Garrido, David Klatzmann, Adrien Six, et al. Behcet’s disease physiopathology: a contemporary review. Auto Immun Highlights. 2016; 7(1): 4.
Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011; 90(2): 125-32.
Rotondo C, Lopalco G, Iannone F. Mucocutaneous involvement in Behcet’s disease: how systemic treatment has changed in the last decades and future perspectives. Mediators Inflamm. 2015: 451-675.
Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007; 48(4): 573-85.
Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H. Frequent oral ulceration during early disease may predict a severe disease course in males with Behcet’s syndrome. Clin Exp Rheumatol. 2012; 30(3): S32-S34.
Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J. 1997; 38(6): 423-7.
Mat MC, Goksugur N, Engin B, Yurdakul S, Yazici H. The frequency of scarring after genital ulcers in Behcet’s syndrome: a prospective study. Int J Dermatol. 2006; 45(5): 554-6.
Saylan T, Mat C, Fresko I, Melikoglu M. Behcet’s disease in the Middle East. Clin Dermatol. 1999; 17(2): 209-23.
Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999; 341(17): 1284-91.
Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E. A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet’s patients. Int J Dermatol. 1998; 37(11): 839-42.
Kutlubay Z, Mat CM, Aydin O. Histopathological and clinical evaluation of papulopustular lesions in Behcet’s disease. Clin Exp Rheumatol. 2015; 33(6): S101-S106.
Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Behcet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 2001; 60(11): 1074-6.
Hatemi G, Fresko I, Tascilar K, Yazici H. Increased enthesopathy among Behcet’s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheumatol. 2008; 58(5): 1539-45.
Lee ES, Bang D, Lee S. Dermatologic manifestation of Behcet’s disease. Yonsei Med J. 1997; 38(6): 380-9.
Demirkesen C, Tuzuner N, Mat C. Clinicopathologic evaluation of nodular cutaneous lesions of Behcet syndrome. Am J Clin Pathol. 2001; 116(3): 341-6.
Bicer A. Musculoskeletal findings in Behcet’s disease. Patholog Res Int. 2012: 653-806.
Yurdakul S, Yazici H, Tuzun Y. The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis. 1983; 42(5): 505-15.
Yurtkuran M, Yurtkuran M, Alp A. Hand involvement in Behcet’s disease. Joint Bone Spine. 2006; 73(6): 679-83.
Fatemi A, Shahram F, Akhlaghi M, Smiley A, Nadji A, Davatchi F. Prospective study of articular manifestations in Behcet’s disease: five year report. Int J Rheum Dis. 2017; 20(1): 97-102.
Yazici H, Tuzlaci M, Yurdakul S. A controlled survey of sacroiliitis in Behcet’s disease. Ann Rheum Dis. 1981; 40(6): 558-9.
Cheon JH, Celik AF, Kim WH. Behcet’s disease: gastrointestinal involvement. In: Yazici Y, Yazici H (editors) Behcet’s syndrome Springer New York 2010: 165-88.
Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behcet disease (Behcet syndrome). Semin Arthritis Rheum. 1979; 8(4): 223-60.
Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behcet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol. 1985; 16(8): 790-5.
Ebert EC. Gastrointestinal manifestations of Behcet’s disease. Dig Dis Sci. 2009; 54(2): 201-7.
Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment and long-term outcome of gastrointestinal involvement in Behcet’s Syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016; 95(16): 3348.
Ozyazgan Y, Ucar D, Hatemi G, Yazici Y. Ocular Involvement of Behcet’s syndrome: a comprehensive review. Clin Rev Allergy Immunol. 2015; 49(3): 298-306.
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004; 138(3): 373-80.
Kural-Seyahi E, Fresko I, Seyahi N. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003; 82(1): 60-76.
Siva A, Saip S. The spectrum of nervous system involvement in Behcet’s syndrome and its differential diagnosis. J Neurol. 2009; 256(4): 513-29.
Uluduz D, Kurtuncu M, Yapici Z. Clinical characteristics of pediatric-onset neuro-Behcet disease. Neurology. 2011; 77(21): 1900-5.
Kocer N, Islak C, Siva A. CNS involvement in neuro-Behcet syndrome: an MR study. AJNR Am J Neuroradiol. 1999; 20(6): 1015-24.
Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behcet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014; 53(11): 2018-22.
Seyahi E. Behcet’s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016; 30(2): 279-95.
Hamuryudan V, Er T, Seyahi E. Pulmonary artery aneurysms in Behcet syndrome. Am J Med. 2004; 117(11): 867-70.
Seyahi E, Melikoglu M, Akman C. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore). 2012; 91(1): 35-48.
Esatoglu SN, Seyahi E, Ugurlu S. Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behcet’s syndrome patients with pulmonary artery involvement during follow-up. Clin Exp Rheumatol. 2016; 34(6): 92-6.
Saadoun D, Asli B, Wechsler B. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine (Baltimore). 2012; 91(1): 18-24.
Ceyran H, Akcali Y, Kahraman C. Surgical treatment of vasculo-Behcet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa. 2003; 32(3): 149-53.
Marzban M, Mandegar MH, Karimi A. Cardiac and great vessel involvement in “Behcet’s disease”. J Card Surg. 2008; 23(6): 765-68.
Emmungil H, Yasar Bilge NS, Kucuksahin O. A rare but serious manifestation of Behcet’s disease: intracardiac thrombus in 22 patients. Clin Exp Rheumatol. 2014; 32(4): S87-S92.
Zhu YL, Wu QJ, Guo LL. The clinical characteristics and outcome of intracardiac thrombus and aortic valvular involvement in Behcet’s disease: an analysis of 20 cases. Clin Exp Rheumatol. 2012; 30(3): S40-S45.
Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifestations in Behcet’s disease. Intractable Rare Dis Res. 2015; 4(2): 70-5.
Ugur Uygunoglu, Sabahattin Saip, Aksel Siva. Behcet’s Disease and Neuro-Behcets Syndrome. EMJ Neuro. 2018; 6(1): 77-85.
Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet. 1990; 335(8697): 1078-80.
Fereydoun Davatchi. Diagnosis/Classification Criteria for Behcet’s Disease. Pathology Research International. 2012.
P. Mansoori, C. Chams, F. Davatchi. “Pathergy phenomenon in Behcet’s disease, new aspects,” in Rheumatology APLAR 1992, A. R. Nasution, J. Darmawan, and H. Isbagio (Editors) Churchill Livingstone Tokyo Japan 1992; 111-3.
C. Chams-Davatchi, F. Davatchi, F. Shahram. “Longitudinal study of the Pathergy phenomenon in Behcet’s disease,” in Behcet’s Disease, M. Hamza (Editor) Pub Adhoua Tunisia 1992; 356-8.
F. Davatchi, C. Chams-Davatchi, F. Shahram. “Pathergy test in Behcet’s disease: Change in incidence over the time”. APLAR Journal of Rheumatology. 2017; 10(4): 333-5.
F. Davatchi, C. Chams-Davatchi, Z. Ghodsi. “Diagnostic value of pathergy test in Behcet’s disease according to the change in incidence over the time”. Clinical Rheumatology. 2011; 30(9): 1151-5.
F. Davatchi, F. Shahram, C. Chams-Davatchi. “How to deal with Behcet’s disease in daily practice”. International Journal of Rheumatic Diseases. 2010; 13(2): 105-16.
International Team for the Revision of the International Criteria for Behcet’s Disease, “Evaluation of the International Criteria for Behcet’s disease (ICBD)”. Clinical and Experimental Rheumatology. 2006; 24(42): S13.
International Team for the Revision of the International Criteria for Behcet’s Disease, “Revision of the International Criteria for Behcet’s Disease (ICBD)”. Clinical and Experimental Rheumatology. 2006; 24(42): S14-S15.
Zouboulis CC. Epidemiology of Adamantiades-Behcet’s disease. Ann Med Interne (Paris). 1999; 150(6): 488-98.
Yazici H, Tuzun Y, Tanman AB. Male patients with Behcet’s syndrome have stronger pathergy reactions. Clin Exp Rheumatol. 1985; 3(2): 137-41.
Sequeira FF, Daryani D. The oral and skin pathergy test. Indian J Dermatol Venereol Leprol. 2011; 77(4): 526-30.
Tugba Kevser Ustunbas Uzuncakmak, Emin Ozlu. Diagnosi/Classification Criteria, Pathergy Test, Activity And Life Quality Scales of Behcet’s Disease. smjournals. 2017.
Fresko I, Yazici H, Bayramicli M, Yurdakul S, Mat C. Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet’s syndrome. Ann Rheum Dis. 1993; 52: 619-20.
Karadag As, Akbay G, Ayd?n M, Astarc? M, Eksioglu M. Comparison of Clinical and Histopathologic Findings of Pathergy Test with Disposable/Sharp and Non disposable/Blunt Needles in Behcet´s Disease. Turk J Med Sci. 2009; 39: 47-51.
Mat C, Yurdakul S, Sevim A, Ozyazgan Y, Tuzun Y. Behcet’s syndrome: facts and controversies. Clin Dermatol. 2013; 31(4): 352-61.
Hatemi G, Silman A, Bang D. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008; 67(12): 1656-62.
Ozguler Y, Leccese P, Christensen R. A systematic literature review on the treatment of major organ involvement of Behcet’s syndrome informing the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2016; 75(2): 800.
Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet’s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015; 33(6): S129-S137.
Akman-Demir G, Saip S, Siva A. Behcet’s disease. Curr Treat Options Neurol. 2011; 13(3): 290-310.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Sireesha Maram, T.Venkataramana Reddy, Hima Bindu Mylapalli, Sudeepthi Padala, Hemanth Kumar Vangala, Aksha Susmitha Jangam
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Sudeepthi Padala, Rett Syndrome: A Review , Journal of Clinical and Pharmaceutical Research: JCPR Volume:1/Issue:1 (2021)
- Hima Bindu Mylapalli, Covid Tongue - A New Symptom of Covid-19 , Journal of Clinical and Pharmaceutical Research: JCPR Volume:1/Issue:2 (2021)
- Hima Bindu Mylapalli, Von Willebrand Disease , Journal of Clinical and Pharmaceutical Research: JCPR Volume:1/Issue:1 (2021)
.